Norga K, Grillet B, Masure S, Paemen L, Opdenakker G
Rega Institute for Medical Research, Leuven, Belgium.
Clin Rheumatol. 1996 Jan;15(1):31-4. doi: 10.1007/BF02231681.
The direct and indirect inhibitory potential of D-penicillamine toward human neutrophil and synovial fluid gelatinase B, a marker enzyme for disease severity in RA, was investigated. Gelatinase and plasminogen activator activities were assessed by SDS-polyacrylamide gel electrophoresis zymography. D-penicillamine significantly inhibits purified and synovial fluid gelatinase B in vitro at concentrations attainable in vivo and also blocks in vitro plasminogen activation. Protease inhibition may be a mechanism of action for D-penicillamine as DMARD.
研究了D-青霉胺对人中性粒细胞和滑膜液明胶酶B（类风湿关节炎疾病严重程度的标志物酶）的直接和间接抑制潜力。通过SDS-聚丙烯酰胺凝胶电泳酶谱法评估明胶酶和纤溶酶原激活剂活性。D-青霉胺在体内可达到的浓度下，能在体外显著抑制纯化的和滑膜液中的明胶酶B，并且还能阻断体外纤溶酶原激活。蛋白酶抑制可能是D-青霉胺作为改善病情抗风湿药的作用机制。
